Enliven Therapeutics (ELVN) Stock Price, Quote, News & History | Benzinga

Enliven Therapeutics Inc (ELVN) Stock Price, Quote, News & History

ELVNNASDAQ

Trade with Public

Trade with Public

$58.92

-0.47-0.79%

At close: Aug 20, 5:00 PM EST

$58.99

0.070.12%

After Hours: 5:17 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$58.95

Close

$58.92

Volume / Avg.

945.52K / 1.40M

Day Range

$57.07 - $59.54

52 Wk Range

14.79 - 62.32

Market Cap

$4.21B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

61

Short Interest

16.63%

Days to Cover

11.44

Recent Enliven Therapeutics, Inc. News

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.

Vandana Singh

Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings

US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Industrials and Enliven Therapeutics lead gains. Dana Inc and Oracle Corp down. Oil up 0.7%, gold down 0.7%. European and Asian markets mixed. Initial jobless claims and producer prices higher than expected.

Avi Kapoor

Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On Thursday

Stitch Fix (SFIX) reported better-than-expected financial results, causing its shares to jump 15.8%. Other big gainers include Velo3D, Virgin Galactic, and Intel.

Avi Kapoor

This Grand Canyon Education Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. See analysts' views on LOPE stock.

Avi Kapoor

CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-66.94M

Investing Cash Flow (TTM)

-390.72M

Financing Cash Flow (TTM)

473.73M

Free Cash Flow (TTM)

-67.04M

Capital Expenditure (TTM)

-98.00K

Net Change in Cash (TTM)

16.07M

Analyst Trends and Forecast

2

Mar

1

May

3

Jun

3

Jul

6

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$3.45B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.86

Earnings Yield % (TTM)

-2.78%

Earnings Yield % (FWD)

-0.47%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$12.22

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$135.51M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$58.95

Close

$58.92

Volume / Avg.

945.52K / 1.40M

Day Range

$57.07 - $59.54

52 Wk Range

14.79 - 62.32

Market Cap

$4.21B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

61

Short Interest

16.63%

Days to Cover

11.44

About

Sector

Health Care

Industry

Pharmaceuticals

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusi...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Enliven Therapeutics (ELVN) stock?

A

You can purchase shares of Enliven Therapeutics (NASDAQ:ELVN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Enliven Therapeutics (ELVN) competitors?

A

Other companies in Enliven Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Enliven Therapeutics (ELVN) stock?

A

Enliven Therapeutics has a consensus price target of $64.60.

Q

What is the current price for Enliven Therapeutics (ELVN)?

A

The stock price for Enliven Therapeutics (NASDAQ: ELVN) is $58.99 last updated August 20, 2026 at 5:17 PM EDT.

Q

Does Enliven Therapeutics (ELVN) pay a dividend?

A

There are no upcoming dividends for Enliven Therapeutics.

Q

When is Enliven Therapeutics (NASDAQ:ELVN) reporting earnings?

A

Enliven Therapeutics does not have any upcoming earnings scheduled.

Q

Is Enliven Therapeutics (ELVN) going to split?

A

There is no upcoming split for Enliven Therapeutics.

Q

What sector and industry does Enliven Therapeutics (ELVN) operate in?

A

Enliven Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.